Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression

S. Hsu, F. Huang, M. Hafez, S. Winawer, E. Friedman

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Transforming growth factor β1 (TGF-β1) switches from an inhibitor of tumor cell growth to a stimulator of growth and invasion during human colon carcinoma progression. We originally observed that metastatic colon carcinoma cells in primary culture responded to TGF-β1 by proliferation, whereas moderate to well-differentiated primary site colon carcinomas were growth inhibited by TGF-β1 (P. Schroy et al., Cancer Res., 50: 261-265, 1990). We then cloned several colon carcinoma cell lines which modeled these responses to TGF-β1 and expressed TGF-β1 (M. M. Hafez et al., Cell Growth and Differ., 1: 617-626, 1990; 3: 753-762, 1992). Two of these colon carcinoma cell lines, U9 and HD3, which activate approximately equal amounts of TGF- β1 and express equal amounts of TGF-β receptors, are now used to compare the effects of TGF-β1 in modulating invasive behavior. The U9 cell line exhibits autocrine-positive growth regulation in vitro by TGF-β1, whereas the HD3 cell line shows the opposite response, autocrine-negative regulation. Blocking endogenous TGF-β1 with isotype-specific antibody inhibited U9 cell growth because autocrine TGF-β1 acts as a mitogen for U9 cells. In contrast, antibody to TGF-β1 stimulated HD3 cell proliferation because autocrine TGF-β1 inhibits growth of these cells. U9 cells were 13-fold more invasive in vitro through a collagen I layer than HD3 cells. In vitro invasion by U9 cells but not by HD3 cells was stimulated 2-fold by TGF-β1, and U9 invasion was inhibited by antibody to TGF-β1. When injected into athymic mice, U9 cells induced tumors 6-fold the size of those induced by HD3 cells. Tumors induced by each cell line retained expression of TGF-β1 in vivo, as shown by immunohistochemistry using isotype-specific antibody. Antibody to TGF-β1 inhibited the growth of U9 cells in athymic mice 4-fold compared to control antibody, demonstrating that autocrine TGF-β1 stimulated U9 cell growth in vivo. Thus, the U9 cells with autocrine-positive growth regulation by TGF-β1 were more tumorigenic in vivo and more invasive in vitro than HD3 cells with autocrine-negative regulation by TGF-β1. Differences in the induction of three immediate early genes were observed between TGF-β1 growth-stimulated U9 cells and TGF-β1 growth-inhibited HD3 cells. Thirty min of TGF-β1 treatment stimulated expression of c-fos approximately 50-fold in TGF-β1 growth-inhibited HD3 cells, whereas only a 2-fold induction was observed in U9 cells. A small increase (50%) in expression of c-jun was seen with TGF-β1 treatment in HD3 cells, whereas expression of c-jun was inhibited in U9. In contrast, c-myc was inhibited 3- 5-fold by exogenous TGF-β1 in both HD3 and U9 cells, suggesting a common role for c-myc in both responses to TGF-β1.

Original languageEnglish (US)
Pages (from-to)267-275
Number of pages9
JournalCell Growth and Differentiation
Volume5
Issue number3
StatePublished - Jan 1 1994

Fingerprint

Transforming Growth Factors
Colon
Carcinoma
Neoplasms
Growth
Antibodies
Cell Line
Nude Mice
N-glycolylneuraminyllactosylceramide

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression. / Hsu, S.; Huang, F.; Hafez, M.; Winawer, S.; Friedman, E.

In: Cell Growth and Differentiation, Vol. 5, No. 3, 01.01.1994, p. 267-275.

Research output: Contribution to journalArticle

Hsu, S. ; Huang, F. ; Hafez, M. ; Winawer, S. ; Friedman, E. / Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression. In: Cell Growth and Differentiation. 1994 ; Vol. 5, No. 3. pp. 267-275.
@article{a750b5a9fc25463489eda6b3e5f091e8,
title = "Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression",
abstract = "Transforming growth factor β1 (TGF-β1) switches from an inhibitor of tumor cell growth to a stimulator of growth and invasion during human colon carcinoma progression. We originally observed that metastatic colon carcinoma cells in primary culture responded to TGF-β1 by proliferation, whereas moderate to well-differentiated primary site colon carcinomas were growth inhibited by TGF-β1 (P. Schroy et al., Cancer Res., 50: 261-265, 1990). We then cloned several colon carcinoma cell lines which modeled these responses to TGF-β1 and expressed TGF-β1 (M. M. Hafez et al., Cell Growth and Differ., 1: 617-626, 1990; 3: 753-762, 1992). Two of these colon carcinoma cell lines, U9 and HD3, which activate approximately equal amounts of TGF- β1 and express equal amounts of TGF-β receptors, are now used to compare the effects of TGF-β1 in modulating invasive behavior. The U9 cell line exhibits autocrine-positive growth regulation in vitro by TGF-β1, whereas the HD3 cell line shows the opposite response, autocrine-negative regulation. Blocking endogenous TGF-β1 with isotype-specific antibody inhibited U9 cell growth because autocrine TGF-β1 acts as a mitogen for U9 cells. In contrast, antibody to TGF-β1 stimulated HD3 cell proliferation because autocrine TGF-β1 inhibits growth of these cells. U9 cells were 13-fold more invasive in vitro through a collagen I layer than HD3 cells. In vitro invasion by U9 cells but not by HD3 cells was stimulated 2-fold by TGF-β1, and U9 invasion was inhibited by antibody to TGF-β1. When injected into athymic mice, U9 cells induced tumors 6-fold the size of those induced by HD3 cells. Tumors induced by each cell line retained expression of TGF-β1 in vivo, as shown by immunohistochemistry using isotype-specific antibody. Antibody to TGF-β1 inhibited the growth of U9 cells in athymic mice 4-fold compared to control antibody, demonstrating that autocrine TGF-β1 stimulated U9 cell growth in vivo. Thus, the U9 cells with autocrine-positive growth regulation by TGF-β1 were more tumorigenic in vivo and more invasive in vitro than HD3 cells with autocrine-negative regulation by TGF-β1. Differences in the induction of three immediate early genes were observed between TGF-β1 growth-stimulated U9 cells and TGF-β1 growth-inhibited HD3 cells. Thirty min of TGF-β1 treatment stimulated expression of c-fos approximately 50-fold in TGF-β1 growth-inhibited HD3 cells, whereas only a 2-fold induction was observed in U9 cells. A small increase (50{\%}) in expression of c-jun was seen with TGF-β1 treatment in HD3 cells, whereas expression of c-jun was inhibited in U9. In contrast, c-myc was inhibited 3- 5-fold by exogenous TGF-β1 in both HD3 and U9 cells, suggesting a common role for c-myc in both responses to TGF-β1.",
author = "S. Hsu and F. Huang and M. Hafez and S. Winawer and E. Friedman",
year = "1994",
month = "1",
day = "1",
language = "English (US)",
volume = "5",
pages = "267--275",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression

AU - Hsu, S.

AU - Huang, F.

AU - Hafez, M.

AU - Winawer, S.

AU - Friedman, E.

PY - 1994/1/1

Y1 - 1994/1/1

N2 - Transforming growth factor β1 (TGF-β1) switches from an inhibitor of tumor cell growth to a stimulator of growth and invasion during human colon carcinoma progression. We originally observed that metastatic colon carcinoma cells in primary culture responded to TGF-β1 by proliferation, whereas moderate to well-differentiated primary site colon carcinomas were growth inhibited by TGF-β1 (P. Schroy et al., Cancer Res., 50: 261-265, 1990). We then cloned several colon carcinoma cell lines which modeled these responses to TGF-β1 and expressed TGF-β1 (M. M. Hafez et al., Cell Growth and Differ., 1: 617-626, 1990; 3: 753-762, 1992). Two of these colon carcinoma cell lines, U9 and HD3, which activate approximately equal amounts of TGF- β1 and express equal amounts of TGF-β receptors, are now used to compare the effects of TGF-β1 in modulating invasive behavior. The U9 cell line exhibits autocrine-positive growth regulation in vitro by TGF-β1, whereas the HD3 cell line shows the opposite response, autocrine-negative regulation. Blocking endogenous TGF-β1 with isotype-specific antibody inhibited U9 cell growth because autocrine TGF-β1 acts as a mitogen for U9 cells. In contrast, antibody to TGF-β1 stimulated HD3 cell proliferation because autocrine TGF-β1 inhibits growth of these cells. U9 cells were 13-fold more invasive in vitro through a collagen I layer than HD3 cells. In vitro invasion by U9 cells but not by HD3 cells was stimulated 2-fold by TGF-β1, and U9 invasion was inhibited by antibody to TGF-β1. When injected into athymic mice, U9 cells induced tumors 6-fold the size of those induced by HD3 cells. Tumors induced by each cell line retained expression of TGF-β1 in vivo, as shown by immunohistochemistry using isotype-specific antibody. Antibody to TGF-β1 inhibited the growth of U9 cells in athymic mice 4-fold compared to control antibody, demonstrating that autocrine TGF-β1 stimulated U9 cell growth in vivo. Thus, the U9 cells with autocrine-positive growth regulation by TGF-β1 were more tumorigenic in vivo and more invasive in vitro than HD3 cells with autocrine-negative regulation by TGF-β1. Differences in the induction of three immediate early genes were observed between TGF-β1 growth-stimulated U9 cells and TGF-β1 growth-inhibited HD3 cells. Thirty min of TGF-β1 treatment stimulated expression of c-fos approximately 50-fold in TGF-β1 growth-inhibited HD3 cells, whereas only a 2-fold induction was observed in U9 cells. A small increase (50%) in expression of c-jun was seen with TGF-β1 treatment in HD3 cells, whereas expression of c-jun was inhibited in U9. In contrast, c-myc was inhibited 3- 5-fold by exogenous TGF-β1 in both HD3 and U9 cells, suggesting a common role for c-myc in both responses to TGF-β1.

AB - Transforming growth factor β1 (TGF-β1) switches from an inhibitor of tumor cell growth to a stimulator of growth and invasion during human colon carcinoma progression. We originally observed that metastatic colon carcinoma cells in primary culture responded to TGF-β1 by proliferation, whereas moderate to well-differentiated primary site colon carcinomas were growth inhibited by TGF-β1 (P. Schroy et al., Cancer Res., 50: 261-265, 1990). We then cloned several colon carcinoma cell lines which modeled these responses to TGF-β1 and expressed TGF-β1 (M. M. Hafez et al., Cell Growth and Differ., 1: 617-626, 1990; 3: 753-762, 1992). Two of these colon carcinoma cell lines, U9 and HD3, which activate approximately equal amounts of TGF- β1 and express equal amounts of TGF-β receptors, are now used to compare the effects of TGF-β1 in modulating invasive behavior. The U9 cell line exhibits autocrine-positive growth regulation in vitro by TGF-β1, whereas the HD3 cell line shows the opposite response, autocrine-negative regulation. Blocking endogenous TGF-β1 with isotype-specific antibody inhibited U9 cell growth because autocrine TGF-β1 acts as a mitogen for U9 cells. In contrast, antibody to TGF-β1 stimulated HD3 cell proliferation because autocrine TGF-β1 inhibits growth of these cells. U9 cells were 13-fold more invasive in vitro through a collagen I layer than HD3 cells. In vitro invasion by U9 cells but not by HD3 cells was stimulated 2-fold by TGF-β1, and U9 invasion was inhibited by antibody to TGF-β1. When injected into athymic mice, U9 cells induced tumors 6-fold the size of those induced by HD3 cells. Tumors induced by each cell line retained expression of TGF-β1 in vivo, as shown by immunohistochemistry using isotype-specific antibody. Antibody to TGF-β1 inhibited the growth of U9 cells in athymic mice 4-fold compared to control antibody, demonstrating that autocrine TGF-β1 stimulated U9 cell growth in vivo. Thus, the U9 cells with autocrine-positive growth regulation by TGF-β1 were more tumorigenic in vivo and more invasive in vitro than HD3 cells with autocrine-negative regulation by TGF-β1. Differences in the induction of three immediate early genes were observed between TGF-β1 growth-stimulated U9 cells and TGF-β1 growth-inhibited HD3 cells. Thirty min of TGF-β1 treatment stimulated expression of c-fos approximately 50-fold in TGF-β1 growth-inhibited HD3 cells, whereas only a 2-fold induction was observed in U9 cells. A small increase (50%) in expression of c-jun was seen with TGF-β1 treatment in HD3 cells, whereas expression of c-jun was inhibited in U9. In contrast, c-myc was inhibited 3- 5-fold by exogenous TGF-β1 in both HD3 and U9 cells, suggesting a common role for c-myc in both responses to TGF-β1.

UR - http://www.scopus.com/inward/record.url?scp=0027930489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027930489&partnerID=8YFLogxK

M3 - Article

C2 - 8018559

AN - SCOPUS:0027930489

VL - 5

SP - 267

EP - 275

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 3

ER -